Concentration‐QTcF analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia
Abstract Quizartinib prolongs QT interval through inhibition of the slow delayed rectifier potassium current (IKs). We used non‐linear mixed‐effects modeling to explore the relationship between quizartinib and its pharmacologically active metabolite AC886 and the Fridericia‐corrected QT interval (QT...
Saved in:
| Main Authors: | Pavan Vaddady, Giovanni Smania, Shintaro Nakayama, Hiroyuki Inoue, Abhinav Kurumaddali, Malaz Abutarif, Ming Zheng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.70065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trial
by: Richard F. Schlenk, et al.
Published: (2025-03-01) -
Targeting oncogenic activation of FLT3/SREBP/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids
by: Feng Yin, et al.
Published: (2025-04-01) -
FLT3 INTERNAL TANDEM DUPLICATION AND D835 MUTATIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND ITS CLINICAL SIGNIFICANCE
by: Ghaleb Elyamany, et al.
Published: (2014-05-01) -
A phase II study of ponatinib for prevention of relapse after allotransplantation in <i>FLT3</i> internal tandem duplication mutation positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial
by: Patrice Chevallier, et al.
Published: (2025-04-01) -
Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation
by: Chen Liang, et al.
Published: (2025-12-01)